nach oben

Erschienen in:

24.09.2019 | Clinical Study

Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma

verfasst von: Kunal S. Patel, Edwin Ng, Taranjit Kaur, Tyler Miao, Tania Kaprealian, Percy Lee, Nader Pouratian, Michael T. Selch, Antonio A. F. De Salles, Quinton Gopen, Stephen Tenn, Isaac Yang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) are noninvasive therapies for vestibular schwannomas providing excellent tumor control. However, delayed hearing loss after radiation therapy remains an issue. One potential target to for improving hearing rates is limiting radiation exposure to the cochlea.

Methods

We retrospectively reviewed 100 patients undergoing either SRS with 12 Gy (n = 43) or fSRT with 50 Gy over 28 fractions (n = 57) for vestibular schwannoma. Univariate and multivariate analysis were carried out to identify predictors of hearing loss as measured by the Gardner Robertson scale after radiation therapy.

Results

Deterioration of hearing occurred in 30% of patients with SRS and 26% with fSRT. The overall long term (> 2 year) progression rates were 20% for SRS and 16% for fSRT. Patients with a decrease in their Gardner Robertson hearing score and those that loss serviceable hearing had significantly higher average minimal doses to the cochlea in both SRS and fSRT cohorts. ROC analysis showed that a cut off of 5 Gy and 35 Gy, for SRS and fSRT respectively, predicted hearing loss with high sensitivity/specificity.

Conclusion

Our data suggests the minimal dose of radiation that the cochlear volume is exposed to is a predictor of delayed hearing loss after either SRS or fSRT. A threshold of 5 Gy/35 Gy may lead to improved hearing preservation after radiotherapy. Further prospective multi center studies can further elucidate this mechanism.

Pinna MH, Bento RF, Neto RV (2012) Vestibular schwannoma: 825 cases from a 25-year experience. Int Arch Otorhinolaryngol 16:466–475. https://doi.org/10.7162/S1809-97772012000400007 CrossRefPubMedCentralPubMed

Arthurs BJ, Lamoreaux WT, Mackay AR et al (2011) Gamma knife radiosurgery for vestibular schwannomas: tumor control and functional preservation in 70 patients. Am J Clin Oncol 34:265–269. https://doi.org/10.1097/COC.0b013e3181dbc2ab CrossRefPubMed

Persson O, Bartek J, Shalom NB et al (2017) Stereotactic radiosurgery vs. fractionated radiotherapy for tumor control in vestibular schwannoma patients: a systematic review. Acta Neurochir 159:1013–1021. https://doi.org/10.1007/s00701-017-3164-6 CrossRef

Rykaczewski B, Zabek M (2014) A meta-analysis of treatment of vestibular schwannoma using Gamma Knife radiosurgery. Contemp Oncol 18:60–66. https://doi.org/10.5114/wo.2014.39840 CrossRef

Mulder JJS, Kaanders JH, van Overbeeke JJ, Cremers CWRJ (2012) Radiation therapy for vestibular schwannomas. Curr Opin Otolaryngol Head Neck Surg 20:367–371. https://doi.org/10.1097/MOO.0b013e328357d337 CrossRefPubMed

Delbrouck C, Hassid S, Massager N et al (2003) Preservation of hearing in vestibular schwannomas treated by radiosurgery using leksell gamma knife: preliminary report of a prospective Belgian clinical study. Acta Otorhinolaryngol Belg 57:197–204PubMed

Paek SH, Chung H-T, Jeong SS et al (2005) Hearing preservation after gamma knife stereotactic radiosurgery of vestibular schwannoma. Cancer 104:580–590. https://doi.org/10.1002/cncr.21190 CrossRefPubMed

Massager N, Nissim O, Delbrouck C et al (2006) Role of intracanalicular volumetric and dosimetric parameters on hearing preservation after vestibular schwannoma radiosurgery. Int J Radiat Oncol Biol Phys 64:1331–1340. https://doi.org/10.1016/j.ijrobp.2005.10.030 CrossRefPubMed

Linskey ME, Johnstone PAS (2003) Radiation tolerance of normal temporal bone structures: implications for gamma knife stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 57:196–200CrossRefPubMed

10.

Massager N, Nissim O, Delbrouck C et al (2013) Irradiation of cochlear structures during vestibular schwannoma radiosurgery and associated hearing outcome. J Neurosurg 119(Suppl):733–739

11.

Thomas C, Di Maio S, Ma R et al (2007) Hearing preservation following fractionated stereotactic radiotherapy for vestibular schwannomas: prognostic implications of cochlear dose. J Neurosurg 107:917–926. https://doi.org/10.3171/JNS-07/11/0917 CrossRefPubMed

12.

Rasmussen R, Claesson M, Stangerup S-E et al (2012) Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss. Int J Radiat Oncol Biol Phys 83:e607–611. https://doi.org/10.1016/j.ijrobp.2012.01.078 CrossRefPubMed

13.

Baschnagel AM, Chen PY, Bojrab D et al (2013) Hearing preservation in patients with vestibular schwannoma treated with Gamma Knife surgery. J Neurosurg 118:571–578. https://doi.org/10.3171/2012.10.JNS12880 CrossRefPubMed

14.

Jacob JT, Carlson ML, Schiefer TK et al (2014) Significance of cochlear dose in the radiosurgical treatment of vestibular schwannoma: controversies and unanswered questions. Neurosurgery 74:466–474. https://doi.org/10.1227/NEU.0000000000000299 (discussion 474)CrossRefPubMed

15.

Kano H, Kondziolka D, Khan A et al (2013) Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma: clinical article. J Neurosurg 119:863–873

16.

Brown M, Ruckenstein M, Bigelow D et al (2011) Predictors of hearing loss after gamma knife radiosurgery for vestibular schwannomas: age, cochlear dose, and tumor coverage. Neurosurgery 69:605–613. https://doi.org/10.1227/NEU.0b013e31821a42f3 (discussion 613–614)CrossRefPubMed

17.

Watanabe S, Yamamoto M, Kawabe T et al (2016) Stereotactic radiosurgery for vestibular schwannomas: average 10-year follow-up results focusing on long-term hearing preservation. J Neurosurg 125:64–72. https://doi.org/10.3171/2016.7.GKS161494 CrossRefPubMed

18.

Pan CC, Eisbruch A, Lee JS et al (2005) Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 61:1393–1402. https://doi.org/10.1016/j.ijrobp.2004.08.019 CrossRefPubMed

19.

Chung LK, Ung N, Sheppard JP et al (2018) Impact of cochlear dose on hearing preservation following stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of vestibular schwannoma. J Neurol Surg B 79:335–342. https://doi.org/10.1055/s-0037-1607968 CrossRef

20.

Pacholke HD, Amdur RJ, Schmalfuss IM et al (2005) Contouring the middle and inner ear on radiotherapy planning scans. Am J Clin Oncol 28:143–147CrossRefPubMed

21.

Ikonomidis C, Pica A, Bloch J, Maire R (2015) Vestibular schwannoma: the evolution of hearing and tumor size in natural course and after treatment by LINAC stereotactic radiosurgery. Audiol Neurootol 20:406–415. https://doi.org/10.1159/000441119 CrossRefPubMed

22.

Akpinar B, Mousavi SH, McDowell MM et al (2016) Early radiosurgery improves hearing preservation in vestibular schwannoma patients with normal hearing at the time of diagnosis. Int J Radiat Oncol Biol Phys 95:729–734. https://doi.org/10.1016/j.ijrobp.2016.01.019 CrossRefPubMed

23.

Aoyama H, Onodera S, Takeichi N et al (2013) Symptomatic outcomes in relation to tumor expansion after fractionated stereotactic radiation therapy for vestibular schwannomas: single-institutional long-term experience. Int J Radiat Oncol Biol Phys 85:329–334. https://doi.org/10.1016/j.ijrobp.2012.05.003 CrossRefPubMed

24.

Okunaga T, Matsuo T, Hayashi N et al (2005) Linear accelerator radiosurgery for vestibular schwannoma: measuring tumor volume changes on serial three-dimensional spoiled gradient-echo magnetic resonance images. J Neurosurg 103:53–58. https://doi.org/10.3171/jns.2005.103.1.0053 CrossRefPubMed

25.

Hanna GG, Murray L, Patel R et al (2018) UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol 30:5–14. https://doi.org/10.1016/j.clon.2017.09.007 CrossRef

26.

Lambrecht M, Eekers DBP, Alapetite C et al (2018) Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiother Oncol 128:26–36. https://doi.org/10.1016/j.radonc.2018.05.001 CrossRefPubMed

27.

Lee T-F, Yeh S-A, Chao P-J et al (2015) Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy. Radiat Oncol 10:194. https://doi.org/10.1186/s13014-015-0501-x CrossRefPubMedCentralPubMed

Titel: Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma
verfasst von: Kunal S. Patel
Edwin Ng
Taranjit Kaur
Tyler Miao
Tania Kaprealian
Percy Lee
Nader Pouratian
Michael T. Selch
Antonio A. F. De Salles
Quinton Gopen
Stephen Tenn
Isaac Yang
Publikationsdatum: 24.09.2019
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-019-03299-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

18.04.2024 | Arterielle Hypertonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Cerebrospinal fluid VEGF levels and angiogenic capacity as potential prognostic markers in patients with gliomas: a pilot study

Ecotropic viral integration site 1 regulates EGFR transcription in glioblastoma cells

Risk factors for intraoperative stimulation-related seizures during awake surgery: an analysis of 109 consecutive patients

Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma

Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens

Communicating hydrocephalus after radiosurgery for vestibular schwannomas: does technique matter? A systematic review and meta-analysis

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Manche Gestagene können das Risiko für Meningeome erhöhen

Parkinson: Größere Studie bestätigt Genauigkeit von Hauttest

Update Neurologie